Dasinib Tablet 100 mg contains Dasatinib, a targeted tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib works by blocking abnormal signals that promote the growth of cancerous white blood cells, helping to control disease progression and improve patient outcomes.

Dasinib Tablet 100 mg is formulated for oral administration, allowing convenient at-home therapy while maintaining precise dosing for optimal efficacy. Its selective action makes it a cornerstone in targeted cancer therapy, providing an effective treatment option for patients resistant or intolerant to prior therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Dasatinib, the active ingredient in Dasinib Tablet, functions as a multikinase inhibitor:

• Inhibition of BCR-ABL tyrosine kinase: Dasatinib binds to the BCR-ABL fusion protein, which is responsible for uncontrolled proliferation of leukemic cells in CML and Ph+ ALL.

• Blocking multiple kinases: In addition to BCR-ABL, Dasatinib inhibits SRC family kinases, c-KIT, and PDGFR, contributing to broader anti-leukemic activity.

• Induction of apoptosis: By disrupting cellular signaling pathways necessary for cancer cell survival, Dasatinib promotes programmed cell death of malignant cells.

• Suppression of proliferation: Dasatinib reduces the growth rate of leukemia cells, helping to control disease progression.

This dual inhibition of BCR-ABL and other tyrosine kinases allows Dasinib Tablet 100 mg to be effective even in patients who have developed resistance to other treatments.

Indications

Dasinib Tablet 100 mg is indicated for the treatment of:

• Chronic myeloid leukemia (CML) – in chronic, accelerated, or blast phases, including patients resistant or intolerant to prior therapy such as imatinib

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) – newly diagnosed or in cases resistant to previous treatments

• Other hematologic malignancies as determined by an oncologist

It is an essential therapy for targeted treatment of leukemias associated with the Philadelphia chromosome, offering improved survival and disease management.

Dosage and Administration

• The recommended adult dose is 100 mg once daily, taken orally with or without food.

• Tablets should be swallowed whole with water; do not crush, split, or chew.

• Regular blood counts and liver function tests are necessary to monitor therapy and detect adverse effects.

• Dose adjustments may be required in cases of side effects or liver impairment.

• Patients should follow their oncologist’s instructions regarding dosing schedules and monitoring for best results.

Precautions and Safety Information

• Use with caution in patients with heart, liver, or kidney disorders.

• Monitor for bleeding complications, fluid retention, or pulmonary arterial hypertension.

• Avoid grapefruit and other foods that may interfere with drug metabolism.

• Inform your doctor about all other medications to prevent interactions.

• Pregnancy and breastfeeding should be avoided during treatment, as Dasatinib may harm fetal development.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Fluid retention and swelling (edema)

• Gastrointestinal symptoms – nausea, vomiting, diarrhea

• Fatigue, headache, or muscle pain

• Rare but serious: pulmonary hypertension, severe bleeding, or liver toxicity

Most side effects are manageable under medical supervision, and regular monitoring is essential for safe therapy.

Storage Instructions

Store Dasinib Tablet 100 mg in a cool, dry place, protected from light and moisture. Keep out of reach of children.

Dasinib Tablet 100 mg provides targeted therapy for Philadelphia chromosome-positive leukemias, controlling abnormal cell growth, supporting remission, and improving quality of life for patients with chronic or resistant leukemia.